Please assess the completion status of the following clinical trial:

Trial Title: Drug to Prevent Pneumonia in the Tube Fed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tube fed for more than four weeks for reason of neurological dysphagia as recommended by a trained speech therapist;~* clinical diagnosis of cerebrovascular diseases, confirmed by CT head scan. The reason for restricting the subjects to those with cerebrovascular disease is that previous studies which showed beneficial effects of ACEI on dysphagia were mostly based on stroke patients.~Exclusion Criteria:~* life expectancy less than six months;~* live outside Shatin area;~* systolic blood pressure less than 100 mm Hg;~* known intolerance of ACEI;~* existing use of ACEI or angiotensin receptor blockers;~* symptomatic chronic lung disease or cardiac failure;~* frequent withdrawal of enteral tube by patients;~* serum creatinine \>100 µmol/L;~* serum potassium \> 5.1 mmol/L.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angiotensin converting enzyme inhibitor (Type: EXPERIMENTAL): Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).